Erytech Competitors

Delisted . USA . 
Stock . Erytech Pharma SA
ERYPDelisted Stock  USD 0.78  0.04  4.88%   
Erytech Pharma SA competes with Genfit, Eliem Therapeutics, HCW Biologics, Aptorum Group, and Surrozen; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Erytech Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Erytech Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Erytech Pharma competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Erytech Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.780.780.78
Details
Intrinsic
Valuation
LowRealHigh
0.740.740.86
Details

Erytech Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Erytech Pharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Erytech and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Erytech Pharma SA does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
APM
+ 0.82
ELYM
SRZN
+ 0.65
GNFT
ACGN
+ 0.61
APM
UNCY
+ 0.46
CYT
ACGN
+ 0.46
ELYM
ADXN
+ 0.41
APM
  
High negative correlations   
UNCY
- 0.75
APM
UNCY
- 0.64
ELYM
ARMP
- 0.59
HCWB
APM
- 0.53
CYT
ADXN
- 0.52
CYT
ELYM
- 0.45
CYT

Risk-Adjusted Indicators

There is a big difference between Erytech Stock performing well and Erytech Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Erytech Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
GNFT  3.07 (0.02)(0.01) 0.09  4.69 
(3.14)
 6.17 
(6.81)
 30.76 
CYT  2.76  0.41  0.13  0.42  2.57 
(3.47)
 10.00 
(5.26)
 36.14 
ELYM  3.92 (0.78) 0.00  0.73  0.00 
 0.00 
 6.21 
(9.35)
 34.87 
HCWB  13.20  4.04  0.35 (1.01) 8.16 
(22.22)
 22.00 
(16.67)
 352.85 
APM  4.55 (1.97) 0.00 (3.18) 0.00 
 0.00 
 5.11 
(10.30)
 47.16 
SRZN  4.79  0.39  0.03 (0.33) 4.87 
(6.15)
 16.74 
(7.91)
 33.59 
UNCY  4.05  0.48  0.10  0.39  4.29 
(5.15)
 9.76 
(7.41)
 29.22 
ARMP  3.07 (0.09) 0.00 (0.19) 0.00 
 0.00 
 6.19 
(7.05)
 33.83 
ADXN  4.44  0.21  0.04  0.34  5.04 
(5.21)
 9.74 
(7.40)
 69.82 
ACGN  5.76 (0.99) 0.00 (0.75) 0.00 
 0.00 
 7.69 
(14.93)
 109.57 
All Fundamental Data

Erytech Pharma Competitive Analysis

The better you understand Erytech Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Erytech Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Erytech Pharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ERYP GNFT CYT ELYM HCWB APM SRZN UNCY ARMP ADXN
 4.88 
 0.78 
Erytech
 1.43 
 4.26 
Genfit
 0.36 
 2.76 
Cyteir
 2.91 
 3.00 
Eliem
 20.78 
 0.61 
HCW
 5.41 
 0.70 
Aptorum
 0.66 
 9.09 
Surrozen
 3.77 
 0.55 
Unicycive
 1.78 
 2.29 
Armata
 5.58 
 7.95 
Addex
Market Volatility
(90 Days Market Risk)
Very steady
Moderately volatile
Very steady
Very risky
Out of control
Somewhat reliable
Risky
Dangerous
Risky
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Weak
Very Weak
Very Weak
Modest
Very Weak
Weak
Good
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Average
Dangerous
Dangerous
High
Very High
Very High
Low
High
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Not Available
Buy
Strong Buy
Buy
Strong Buy
Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Current Ratio
2.25
6.33
19.95
17.48
30.25
1.14
11.12
4.43
5.59
2.55
Net Asset
45.81 M
173.87 M
153.23 M
110.47 M
28.51 M
20.64 M
46.08 M
14.19 M
98.36 M
4.64 M
Profit Margin
-0.0343
0.28
N/A
N/A
N/A
N/A
N/A
N/A
N/A
5.0
EBITDA
(22.69 M)
(22.24 M)
(33.41 M)
(40.27 M)
(23.58 M)
(9.6 M)
(41.13 M)
(30.18 M)
(39.92 M)
(10.23 M)
Operating Margin
-4.08
0.51
N/A
N/A
-22.36
-24.86
0.12
N/A
-11.31
-7.8
Current Valuation
211.16 K
218.56 M
(20.89 M)
122.66 M
37.32 M
5.2 M
55.66 K
25.82 M
206.04 M
3.95 M
Price To Book
0.65
2.06
0.87
1.56
2.8
0.16
5.21
2.06
4.06
0.56
Retained Earnings
(228 K)
(389.79 M)
(138.11 M)
(155.98 M)
(70.53 M)
(68.16 M)
(221.69 M)
(64.54 M)
(308.82 M)
(360.42 M)
Current Asset
94.53 M
305.96 M
834.8 M
N/A
N/A
25.7 M
N/A
N/A
4.48 M
32.02 M
Beta
2.13
1.12
0.096
-0.35
0.84
1.3
0.94
2.29
0.81
1.87
Number Of Employees
49
169
46
9
45
3
42
14
66
23
Shares Outstanding
34.12 M
49.91 M
36 M
67.06 M
37.82 M
3.81 M
3.25 M
103.8 M
36.18 M
1.07 M
Cash Flow From Operations
(31.76 M)
(55.43 M)
(25.79 M)
(20.6 M)
(22.51 M)
(7.72 M)
(40.36 M)
(18.28 M)
(47.42 M)
(7.99 M)
Total Debt
13.57 M
70.18 M
889 K
349 K
6.3 M
3.28 M
3.38 M
811 K
120.37 M
344.34 K
Return On Equity
-0.0098
0.26
-0.24
-0.38
-3.44
-0.37
-1.74
-1.22
-34.39
-1.26
Z Score
0.48
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.3
0.0651
-0.14
-0.25
-0.7
-0.32
-0.33
-0.53
-0.25
-0.62
Number Of Shares Shorted
17.79 K
63.36 K
319.73 K
1.15 M
8.09 K
4.6 K
34.89 K
1.05 M
4.54 K
3.46 K
Book Value Per Share
0.76
1.96
3.47
3.33
-0.17
4.8
1.76
-0.11
-0.89
0.009
Current Liabilities
9.8 M
44.21 M
366.9 M
N/A
N/A
10.9 M
N/A
N/A
4.08 M
4.82 M
Total Asset
45.81 M
173.87 M
153.23 M
110.47 M
28.51 M
20.64 M
46.08 M
14.19 M
98.36 M
4.64 M
Debt To Equity
1.0
0.68
0.017
0.004
0.005
0.23
0.073
0.023
0.73
0.049
Short Ratio
0.1
3.73
3.07
4.07
0.28
0.2
1.32
0.74
0.86
0.14
Target Price
2.96
9.73
3.0
4.5
3.0
80.0
33.0
5.5
7.0
30.0
Shares Owned By Institutions
7.65
0.25
76.83
77.67
3.1
1.45
77.18
38.2
3.82
0.16
Market Capitalization
29.57 M
214.63 M
108.71 M
346.03 M
11.95 M
4.15 M
29.54 M
57.36 M
82.86 M
8.64 M
Price To Earning
-5.88
4.72
0.36
N/A
N/A
2.7
N/A
N/A
-1.64
N/A
Price To Earnings To Growth
N/A
N/A
-0.03
N/A
N/A
N/A
-0.05
N/A
N/A
N/A
Price To Sales
7.58
2.67
N/A
N/A
6.51
9.62
2.95
62.82
22.28
10.01
Net Income
(228 K)
(28.89 M)
(33.22 M)
(35.12 M)
(24.99 M)
(4.34 M)
(43.04 M)
(30.54 M)
(69.05 M)
(10.56 M)
Earnings Per Share
-0.01
0.39
-0.93
-2.22
-1.05
-0.59
-16.94
-0.46
-1.17
-18.94
Shares Owned By Insiders
N/A
N/A
6.63
10.38
52.3
23.71
1.6
6.73
70.24
N/A
Revenue
N/A
28.57 M
N/A
N/A
2.84 M
431.38 K
12.5 M
675 K
4.53 M
1.61 M
Working Capital
30.96 M
74.64 M
143.89 M
107.42 M
(2.34 M)
377.34 K
33.98 M
(4.13 M)
2.69 M
1.34 M
Cash And Equivalents
54.05 M
209.12 M
166.4 M
122.95 M
32.41 M
4.22 M
92.69 M
10.57 M
36.98 M
8.81 M
Cash Per Share
1.74
4.21
4.71
4.63
0.9
0.12
2.64
0.7
1.02
1.4
Gross Profit
4.18 M
26.25 M
(16.59 M)
N/A
4.1 M
81.85 K
N/A
N/A
(29.51 M)
1.44 M
Day Typical Price
0.8
4.32
2.77
3.01
0.64
0.71
9.33
0.55
2.26
7.79
Accumulation Distribution
0.0714
0.0449
0.0214
0.0705
0.23
0.0541
0.1
0.0536
0.0975
0.0713
Market Facilitation Index
0.06
0.2
0.06
0.22
0.17
0.04
1.01
0.03
0.23
0.57
Daily Balance Of Power
(0.67)
0.3
0.1667
(0.41)
(0.94)
(1.00)
(0.06)
0.6667
0.1739
0.7368
Period Momentum Indicator
(0.04)
0.06
0.01
(0.09)
(0.16)
(0.04)
(0.06)
0.02
0.04
0.42
Rate Of Daily Change
0.95
1.01
1.0
0.97
0.79
0.95
0.99
1.04
1.02
1.06
Day Median Price
0.81
4.35
2.78
3.01
0.66
0.72
9.45
0.55
2.25
7.71
Price Action Indicator
(0.05)
(0.06)
(0.01)
(0.06)
(0.12)
(0.04)
(0.38)
0.015
0.065
0.46
Coefficient Of Variation
(9,435)
6390.11
956.88
(585.70)
1147.78
(423.03)
2238.57
764.64
(10,895)
2415.7
Mean Deviation
4.72
3.07
2.76
3.92
13.2
4.55
4.79
4.05
3.07
4.44
Jensen Alpha
(0.01)
(0.02)
0.406
(0.78)
4.04
(1.97)
0.388
0.4795
(0.09)
0.2102
Total Risk Alpha
(1.19)
(0.64)
(0.29)
(1.77)
(2.84)
(3.13)
(0.74)
(0.14)
(0.77)
(0.93)
Sortino Ratio
N/A
(0.01)
0.1261
N/A
0.3474
N/A
0.0338
0.0987
N/A
0.0383
Downside Variance
N/A
26.11
12.58
N/A
101.26
N/A
24.68
33.52
N/A
28.89
Standard Deviation
7.09
4.53
5.51
5.39
41.6
7.98
6.63
5.35
4.64
8.08
Kurtosis
3.14
3.48
24.66
2.47
58.91
11.31
2.03
1.39
7.58
24.09
Potential Upside
12.68
6.17
10.0
6.21
22.0
5.11
16.74
9.76
6.19
9.74
Treynor Ratio
0.139
0.0878
0.4198
0.7333
(1.01)
(3.18)
(0.33)
0.3891
(0.19)
0.3367
Maximum Drawdown
46.27
30.76
36.14
34.87
352.85
47.16
33.59
29.22
33.83
69.82
Variance
50.23
20.57
30.37
29.04
1730.8
63.61
44.0
28.63
21.49
65.3
Market Risk Adjusted Performance
0.149
0.0978
0.4298
0.7433
(1.00)
(3.17)
(0.32)
0.3991
(0.18)
0.3467
Risk Adjusted Performance
8.0E-4
0.0203
0.0885
(0.12)
0.0764
(0.17)
0.043
0.1085
0.0013
0.0407
Skewness
1.01
(0.29)
4.05
0.1646
7.48
(0.58)
1.17
0.5561
1.4
3.75
Semi Deviation
N/A
4.69
2.57
N/A
8.16
N/A
4.87
4.29
N/A
5.04
Information Ratio
(0.03)
(0.01)
0.0812
(0.19)
0.084
(0.25)
0.0253
0.1067
(0.04)
0.0255
Value At Risk
(8.25)
(6.81)
(5.26)
(9.35)
(16.67)
(10.30)
(7.91)
(7.41)
(7.05)
(7.40)
Expected Short fall
N/A
(3.14)
(3.47)
N/A
(22.22)
N/A
(6.15)
(5.15)
N/A
(5.21)
Downside Deviation
N/A
5.11
3.55
N/A
10.06
N/A
4.97
5.79
N/A
5.38
Semi Variance
N/A
21.95
6.6
N/A
66.6
N/A
23.72
18.43
N/A
25.43

Erytech Pharma Competition Performance Charts

Five steps to successful analysis of Erytech Pharma Competition

Erytech Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Erytech Pharma SA in relation to its competition. Erytech Pharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Erytech Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Erytech Pharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Erytech Pharma SA, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Erytech Pharma position

In addition to having Erytech Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Gambling Thematic Idea Now

Gambling
Gambling Theme
Companies that are related to providing gambling services across multiple geographical areas by investing, exploring, or producing software, hardware, and related infrastructure for running gambling operations or trading speculative assets. The Gambling theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gambling Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Consideration for investing in Erytech Stock

If you are still planning to invest in Erytech Pharma SA check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Erytech Pharma's history and understand the potential risks before investing.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY